Regulatory & Legal

MJP Wealth Advisors President Brian Vendig joins the elite Barron’s 2026 list, a nod to the firm's rapid growth and sophisticated client strategies.

Enlivex reported a staggering $1.23 billion profit, not from its labs, but from a risky treasury of crypto assets. Is this genius or a gamble?

A landmark settlement by Jushi Holdings sets a new precedent in the fight against unregulated hemp products, highlighting deep industry rifts and public safety risks.

A landmark report reveals Gen Z nurses demand more connection and flexibility, forcing healthcare to abandon old management styles or risk a deeper crisis.

A new partnership aims to bring industrial-scale, clean-label cannabis extraction to the Garden State, promising a new standard for purity and consistency.

With cash dwindling and no FDA approval, ENDRA is exploring a sale. Will its innovative TAEUS® liver scanner find a champion or fade into obscurity?

A new partnership aims to bring therapy animals to 100,000 patients and staff, tackling burnout with a dose of compassion and scientific backing.

AccessLex Institute's ABA Grassroots Award highlights its vital research on lawyer debt, shaping policy and offering a lifeline to young professionals.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

A new survey reveals inflation and a desire for connection are pushing retirees back into the workforce, not for full-time jobs, but for flexible roles.

Canada's oldest brewery celebrates the Artemis II mission with an out-of-this-world, non-alcoholic, freeze-dried lager. Is this the future of food?

A deepening helium shortage, driven by Mideast conflict, threatens the global tech industry and sparks a high-stakes hunt for new, stable sources.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

With €10M in new funding, Berlin-based Cellbricks is moving its biofabricated human tissues from lab to preclinical trials, promising a new era for patients.

Maze Therapeutics posts positive Phase 2 data for its genetic kidney disease drug, but a sharp stock drop reveals investor concerns in a competitive race.

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

With a new $200M funding round, legal AI leader Harvey is now valued at $11 billion, signaling a fundamental shift in how law is practiced worldwide.

NexGold launches a massive 30,000-meter drill program at its Goldboro project, a strategic move to upgrade resources and pave the way for a final investment decision.

GSD seeks dual US-based accreditations, a strategic move to bolster its global standing and elevate student value in a competitive academic landscape.

As funding expires for Wayne State's 35-year heart experiments on dogs, advocates and lawmakers urge the NIH to end a legacy of waste and suffering.